2023-10-11 09:52:52 ET
A New Jersey-based %Biotech company is catching a serious premarket bid this morning following a press release detailing the company’s announcement that they completed clinical resolution of a patient’s recurrent hemorrhagic cystitis due to Candida krusei, a fluconazole inherited resistant fungal pathogen, following treatment with the company’s MAT2203.
Traders immediately got excited about this news as shares of %MatinasBiopharmaHoldings (NYSE American: ) are currently bid up at $0.2693/share (+73.74% implied open for sellers) at the time of writing. This should be an exciting session for this micro cap!
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.
About AllPennyStocks.com Media Inc.:
AllPennyStocks.com Media, Inc., founded in 1999, is one of North America’s largest and most comprehensive small-cap / penny stock financial portals. With Canadian and U.S. focused penny stock features and content, the site offers information for novice investors to expert traders.